ADRB3 and metabolic dysfunction-associated steatotic liver disease: Therefore, we hypothesized that liver β3-AR is upregulated when the sympathetic nervous system is activated in the context of NAFLD and that application of the β3-AR agonist BRL37344 will reduce lipid accumulation and inflammation in the liver.